Cargando…
CCL21-DC in situ vaccination in murine NSCLC overcomes resistance to immunotherapy and generates systemic tumor-specific immunity
BACKGROUND: Despite recent advances in immunotherapy, many patients with non-small cell lung cancer (NSCLC) do not respond to immune checkpoint inhibitors (ICI). Resistance to ICI may be driven by suboptimal priming of antitumor T lymphocytes due to poor antigen presentation as well as their exclusi...
Autores principales: | Salehi-Rad, Ramin, Lim, Raymond J, Du, Yushen, Tran, Linh M, Li, Rui, Ong, Stephanie L, Ling Huang, Zi, Dumitras, Camelia, Zhang, Tianhao, Park, Stacy J, Crosson, William, Kahangi, Bitta, Abascal, Jensen, Seet, Christopher, Oh, Michael, Shabihkhani, Maryam, Paul, Manash, Krysan, Kostyantyn, Lisberg, Aaron E, Garon, Edward B, Liu, Bin, Dubinett, Steven M |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BMJ Publishing Group
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10510892/ https://www.ncbi.nlm.nih.gov/pubmed/37730274 http://dx.doi.org/10.1136/jitc-2023-006896 |
Ejemplares similares
-
Novel Kras-mutant murine models of non-small cell lung cancer possessing co-occurring oncogenic mutations and increased tumor mutational burden
por: Salehi-Rad, Ramin, et al.
Publicado: (2021) -
Single-Cell Characterization of Pulmonary Nodules Implicates Suppression of Immunosurveillance across Early Stages of Lung Adenocarcinoma
por: Yanagawa, Jane, et al.
Publicado: (2023) -
Chronic IL-1β-induced inflammation regulates epithelial-to-mesenchymal transition memory phenotypes via epigenetic modifications in non-small cell lung cancer
por: Li, Rui, et al.
Publicado: (2020) -
Author Correction: Chronic IL-1β-induced inflammation regulates epithelial-to-mesenchymal transition memory phenotypes via epigenetic modifications in non-small cell lung cancer
por: Li, Rui, et al.
Publicado: (2020) -
IMMU-08. reMATCH PROTOCOL: PHASE II STUDY OF EX-VIVO EXPANDED AUTOLOGOUS TUMOR SPECIFIC LYMPHOCYTE TRANSFER (X-ALT) + TOTAL TUMOR RNA DC VACCINE (TT-RNA DC) DURING RECOVERY FROM MYELOABLATIVE CHEMOTHERAPY (MAC) AND PERIPHERAL BLOOD STEM CELL (PBSC) RESCUE OR NON-MYELOABLATIVE CHEMOTHERAPY (NMAC) AND PBSC IN PATIENTS (PTS) WITH RECURRENT PNET (R-PNET)
por: Gururangan, Sridharan, et al.
Publicado: (2020)